Potential anti-HER2 target therapy beneficiaries: can MRI radiomics identify the status of HER2-low in breast cancer?

Recently, HER2-low expression tumor was proposed as a new entity in the field of breast cancer and radiomics studies related to HER2-low are rare. This study investigated whether multiparametric MRI-based radiomics can distinguish HER2- low from HER2-positive and HER2-zero in breast cancer. Results showed that clinico-radiomics nomograms including hormone receptor status and radiomics signatures combined contrast-enhanced T1-weighted and apparent diffusion coefficient map performed best in both prediction tasks: HER2-positive vs. HER2-negative and HER2-low vs. HER2-zero. This suggests that multiparametric MRI radiomics achieved effective prediction of HER2-low, which might be further guidance of the anti-HER2 targeted therapy in breast cancer.